Sanford Burnham Prebys Medical Discovery Institute’s Sumit Chanda, PhD led a powerful team of scientists that have identified at least 21 existing drugs that stop the replication of SARS-CoV-2, the virus behind COVID-19. By analyzing the world’s largest collections of known drugs via Scripps Research ReFRAME library, the team reported 100 molecules with confirmed antiviral activity in the laboratory environment. The independent scientists further identified 21 actual drugs that at effective concentrations could be safety administered to patients. Four of these compounds could actually work synergistically with remdesivir, the current standard-of-care in the United States and some other nations. The top candidates include Clofazimine, Hanfangchin A, Apilimod and ONO 5334.
The Drug Library: ReFRAME Courtesy of Scripps Research
The research team leveraged the robust ReFRAME drug repurposing collection, what they claim is the most comprehensive drug repurposing collection of compounds that have been approved by the U.S. Food and Drug Administration (FDA) for other diseases or that have been tested extensively for human safety.
Apparently, ReFRAME was initially set up to help...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).